|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.77 SEK | +0.27% |
|
-2.08% | +40.15% |
| Mar. 13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
| Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
CombiGene AB (publ) reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was SEK 84.04 million. Net income was SEK 20.97 million compared to net loss of SEK 29.38 million a year ago.
Basic earnings per share from continuing operations was SEK 1.21. Diluted earnings per share from continuing operations was SEK 1.21.
| 1st Jan change | Capi. | |
|---|---|---|
| +40.15% | 6.81M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
COMBIGENE AB 
